Pharming Group Interim Report on Financial Results for the First Quarter 2017
Pharming Group N.V. presents its (unaudited) financial report for the quarter ended 31 March 2017.
Operating profitability achieved, with a 794% increase in revenues from product sales, demonstrating the benefits of reacquiring RUCONEST® commercialisation rights in the US.
“The first quarter was very active for Pharming and importantly, it was the first full quarter in which we received all of the benefits of the acquisition of commercialization rights for RUCONEST® in North America from certain subsidiaries.''- Sijmen de Vries - CEO